abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

7 May 2015

Author:
Shreerupa Mitra Jha, Outlook

WHO adds 36 new drugs to list of essential medicines, some beyond the reach of most patients

The WHO...added 36 new drugs to the list of essential medicines, including groud-breaking new treatment for hepatitis C and multi-drug resistant tuberculosis (TB), but some experts said prices needed to fall to make them accessible to patients in poorer countries...However, some of the medicines in the list are exorbitantly priced and beyond the reach of most patients...the price of Gilead's sofosbuvir...to cure hepatitis C, has been the subject of fierce debate with its USD 1000 a pill price tag...Though Gilead has agreed to grant voluntary licences to 11 Indian generic companies for bringing the prices down for low-income countries, Medecins Sans Frontières (MSF) who treat hepatitis C patients in the poorest folds of the world, had told Business and Human Rights Resource Centre, that some of the conditions imposed were not acceptable.